FreeStyle Libre monitoring in T2DM
Research type
Research Study
Full title
Effect of introduction of FreeStyle Libre monitoring on glycaemic control in people with type 2 diabetes mellitus (T2DM)
IRAS ID
301630
Contact name
Thozhukat Sathyapalan
Contact email
Sponsor organisation
Hull University Teaching Hospitals NHS Trust
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 6 months, 2 days
Research summary
Type 2 diabetes(T2D) is a global health problem resulting in a variety of life-changing complications that can be minimized by effective sugar control. There are numerous oral and injectable medications including insulin which are used to treat T2D worldwide. FreeStyle Libre (FSL)monitoring is a form of glucose monitoring used in patients with Type 1 diabetes(T1D)that has resulted in improved sugar control in patients. We believe that this effect seen in people with T1D can be seen in T2D as well, and if proven, will help to reduce medication burden and at the same time result in better sugar control. To assess whether FSL monitoring improves sugar control in people with T2D, we will recruit a total of 40 participants, randomly allocating 20 to receive the FreeStyle Libre 2 sensor system (Libre 2) and 20 to receive the FreeStyle Libre pro iQ monitoring system (Libre pro iQ)(glucose readings are masked from the patients so this will be the control group)and study the change in sugar control over 3 months. The recruitment process will take place at the Allam Diabetes Centre in the Hull Royal Infirmary. This study is sponsored by the R&D department of the Hull University Teaching Hospitals NHS Trust and is funded through the University of Hull.
REC name
West Midlands - Black Country Research Ethics Committee
REC reference
22/WM/0152
Date of REC Opinion
10 Aug 2022
REC opinion
Further Information Favourable Opinion